• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

July 21-22, 2011: Tobacco Products Scientific Advisory Committee Meeting Announcement

Date:   July 21-22, 2011

Time: The meeting will be open to the public from 9:00 a.m. to 5:00 p.m. on July 21, 2011 and from 8:00 a.m. to 12:00 p.m. on July 22, 2011.

Location: 

Center for Tobacco Products
9200 Corporate Blvd.
Rockville, MD 20850

Seating for this meeting may be limited, so the public is encouraged to watch the free webcast instead of traveling to the meeting.The link for the webcast will be available by 9:00 a.m. on July 21, 2011, on the TPSAC website. The link will become active shortly before the open session begins at 9:00  a.m. on July 21, 2011.

Agenda:     

On the morning of July 21, 2011, the Committee will discuss changes proposed by Committee members to the TPSAC Menthol Report submitted to the agency on March 18, 2011.  The Committee will consider additional oral and written comments from the public.  The Committee will consider and deliberate on proposed changes to the report and adopt amendments that constitute the advice of the Committee.  Redacted versions of the document, reflecting the changes to the report proposed by the Committee members, will be made available on the FDA website, no later than June 22, 2011.  

On the afternoon of July 21, 2011, and on July 22, 2011, the Committee will initiate discussions on the issue of the nature and impact of the use of dissolvable tobacco products on the public health.  These discussions will begin the process for the Tobacco Products Scientific Advisory Committee’s required report to the Secretary of Health and Human Services regarding the issue of the nature and impact of the use of dissolvable tobacco products on the public health, including such use among children.   The final report should take under consideration (1) the risks and benefits to the population as a whole including users and nonusers of tobacco products; (2) the increased or decreased likelihood that existing users of tobacco products will stop using such products; and (3) the increased or decreased likelihood that those who do not use tobacco products will start using such products.

Meeting Materials:

Links to meeting materials will be added as they become available.  FDA intends to make the complete background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting.

Public Participation Information:

Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.

• Written submissions may be made to the contact person on July 5, 2011.  Please send 20 paper copies, and one electronic copy, of your submission to:

Caryn Cohen, M.S.
Office of Science
Center for Tobacco Products
Food and Drug Administration
9200 Corporate Blvd.
Rockville, MD 20850

Copies must be received by 4 p.m. (Eastern) on July 5, 2011.

• Oral presentations from the public will be scheduled between approximately 10 a.m. and 11 a.m. on both July 21, 2011 and July 22, 2011.  Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before June 27, 2011.

Time allotted for each presentation may be limited.  If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session.  The contact person will notify interested persons regarding their request to speak by June 27, 2011.

Contact Information:

• Caryn Cohen, M.S.
  Center for Tobacco Products
  Food and Drug Administration
  9200 Corporate Boulevard
  Rockville, MD 20850

  Phone:  1-877-287-1373 (choose Option 4) 
  FAX:  240-276-3761 
  Email:  TPSAC@fda.hhs.gov 

• FDA Advisory Committee Information Line
  1-800-741-8138
  (301-443-0572 in the Washington DC area)
  Code: 8732110002
  Please call the Information Line for up-to-date information on this meeting.

A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice.  Therefore, you should always check the agency’s Website and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.

FDA intends to make background material available to the public no later than 2 business days
before the meeting.  If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting.

Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.  FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs.  If you require special accommodations due to a disability, please contact Caryn Cohen at least 7 days in advance of the meeting.  FDA is committed to the orderly conduct of its advisory committee meetings. 

Please visit our Web site at http://www.fda.gov/oc/advisory/default.htm for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).